Kare 11 local news just read, in full, this statement from Michael and Susan Pretti, the parents of Alex Pretti. "Please get the truth out about our son."

If you stop taking blood pressure meds, your BP goes up. We call that medicine. If you stop taking GLP-1s, your weight goes up. Scientists are calling it "weight recidivism"—a term for convicted criminals. Why is obesity still treated as a moral failure? #GLP open.substack.com/pub/overmatt...

While there is so much that is disturbing about this case study in the destruction of academic freedom, one high point is the refusal of the targeted professor to submit

We sent in our letter and I know Min. Joly received it. This was not part of the ask. Investing directly in tri-council is a better use of these funds. We already have a recruitment advantage over the US now. We need to value what we already and invest in Canadian research sovereignty

Canadian scientist here. I don't want this. I want you to fund our excellent early career scientists who do great work in Canada. Fund them properly and that will help 1000x more than recruiting handfuls of cherry picked bigwigs from Harvard, Stanford and MIT who will leave after a few years.

🚨 Just published! This guideline provides multi-disciplinary clinical teams with practical recommendations for SGLT2is, MRAs, ARNI and drugs with GLP-1 receptor agonist activity. Read the guideline here: onlinecjc.ca/article/S082... #Cardiosky #HeartFailure

Also check out @hildabast.bsky.social post on PubMed alternatives absolutelymaybe.plos.org/2025/02/14/w...

Comparison of Quadruple Therapy Sequencing Strategies for Heart Failure With Reduced Ejection Fraction | Journal of the American Heart Association www.ahajournals.org/doi/10.1161/...

DIGIT-HF + DIG pooled (DIG: composite of all-cause death & HF hospitalization calculated using IPD since this endpoint was not originally reported in the trial manuscript):

DIGIT-HF trial - more to say on this later, but my initial thoughts can be summarized in a classic gif. www.nejm.org/doi/full/10....

Differences in indications, contraindications, and prescribing patterns for heart failure between specialties: the VancOuver CoastAL Acute Heart Failure (VOCAL-AHF) registry www.sciencedirect.com/science/arti...

Our meta-analysis that I presented at ESC last year now published & available open-access: Evening Blood Pressure Medication Administration and Cardiovascular Events: Systematic Review and Meta-Analysis - Canadian Journal of Cardiology onlinecjc.ca/article/S082...

🧠 In @nejm.org, Raja-Elie Abdulnour et al. warn: AI in medical training risks deskilling & mis-skilling. They propose DEFT-AI to teach critical thinking & safe human-AI collaboration. Verify, then trust. 📖 doi.org/10.1056/NEJM... #ResearchEthics #MedicalEducation

Apropos of nothing today ;) (One potential / my) Shared decision-making approach to type 2 diabetes management www.cfp.ca/content/70/5...

We made a new decision aid! Introducing CR-DECIDE: decisionaid.ca/cr-decide/ A brief 🧵 on how we developed it & how it can be used 1/7

Development and Validation of the CR-DECIDE Models to Predict Major Adverse Cardiovascular Events and Health Status in Stable Coronary Artery Disease - CJC Open www.cjcopen.ca/article/S258...

ICE killed a Canadian man.

ACHIEVE trial - Spironolactone in Hemodialysis stopped early... due to futility 😢 I had some hopes for this one. #ERA25

It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25 journals.sagepub.com/doi/10.1177/...

There you have it: BEDMED published in @jama.com jamanetwork.com/journals/jam... h/t @drjmluther.bsky.social No difference in bedtime versus morning BP meds - as expected #NephSky #Hypertension 1/

Also summarized in the @ahajournals.bsky.social HT journal here www.ahajournals.org/doi/10.1161/... feat @rickyturgeon.bsky.social @mikejohansenmd.medsky.social @jordybc.bsky.social @boback.bsky.social and more! 4/

No need to accuse anyone of fraud - focus on trustworthiness of data. I suggest following Cochrane policy for managing potentially problematic studies: www.cochranelibrary.com/cdsr/editori...

This brings us to the "simplified" risk-of-bias tool that doesn't have an actual problem to solve, nor add anything. But why not gather friends, throw opinions around, load up the CV, and then lament the continued explosion of low quality systematic reviews. www.bmj.com/content/388/... end/

FRESH-UP is my favorite trial of 2025 so far (despite some superiority design limitations). My takeaway: In patients with chronic HF, liberalizing fluid intake vs restricting <1.5L doesn't worsen HF symptoms or require higher diuretic doses, among euvolemic patients on good GDMT 1/ rdcu.be/efInN

Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ bit.ly/3DYGHEl #CardioSky #MedSky

In clinical research, you will often receive feedback on study design, stats, and/or data analysis from an editor or reviewer that is simply wrong. Here is a list of common "statistical myths" and references you can use to push back. discourse.datamethods.org/t/reference-...

What a journey this paper took. Hydroxychloroquine was the first (false) hope of the pandemic. Trump touted it and took it himself. Even my hospital at the time, Yale, jumped on the bandwagon, briefly using it. But researchers and patients generated RCT data showing it doesn’t work for COVID.

Stumbled upon a neat website from @rickyturgeon.bsky.social, with guides on analyzing clinical trials and useful summaries mostly in heart failure #cardiosky nerdcat.org

"In randomized experiments, the effects of this variable are distributed among the groups by the randomization in a way that is taken into account in the standard tests of significance. ." Cochran 1957. NB "distributed". He does not say "balanced." See also errorstatistics.com/2020/04/20/s...

Updated prior NERDCAT summary of GLP1 receptor agonists in HFpEF with data from SUMMIT: nerdcat.org/studysummari... #cardiosky #nephsky #medsky How do people feel about the "incretin analog" terminology? Still feels clumsy to me

[citation needed] Nearly every article on MRAs in HF (+++ in the last few days) make this statement without any supporting evidence, which hurts their credibility. What am I missing? Is this merely based on (unsubstantiated) mechanistic differences, or is there evidence I've not yet seen? #cardiosky

As well as prognostic factors that *aren't* imbalanced! It's amazing. Links to good advice on "how" in the post below.

Even though the observed rates were lower than assumed (22%), had NI margin been fixed as risk ratio of 1.18 ([22+4]/22), the overall results would still have met NI as RR was 0.90, 0.77-1.05. An excellent example of how a NI trial should be designed and executed. Congrats to trial investigators.

I've previously been critical of non-inferiority (NI) trials in ID, usually because of bus-sized NI margins allowing almost any result to be able to claim NI, but this is a great one. Certainly better than recent examples of NI trials in cardiology, which have become egregiously biased to show NI

Feels right that my 1st post here should be to share this incredible RCT, led by my PhD supervisor Nick Daneman: www.nejm.org/doi/full/10.... Main takeaway: 7-days of abx should be the standard of care for patients with uncomplicated non-S. aureus BSI. A deep dive 🧵: #IDsky

The Chronicles of Chronotherapy in hypertension, on MARKUS @ Home with @rickyturgeon.bsky.social Scott Garrison And Isla Mackenzie #HTSky www.youtube.com/watch?v=mqkT...

Going to #AHA24? Come check out our latest modeling study of pharmacotherapy for heart failure with reduced ejection fraction, this time looking at 1-year efficacy/safety of different quadruple therapy sequencing strategies: eppro01.ativ.me/appinfo.php?...